Alphabet's Isomorphic Labs In Drug Discovery Deals With Eli Lilly, Novartis
·1 min
Isomorphic Labs, a unit of a technology giant, recently announced strategic research collaborations with two pharmaceutical companies. The collaborations will focus on the development of small-molecule treatments for multiple targets. Isomorphic Labs, which uses artificial intelligence in drug discovery, will receive upfront cash and potential milestone payments. The first collaboration involves the discovery of small molecule therapeutics across various targets with one pharmaceutical company. The second collaboration focuses on finding small molecule therapeutics against three targets with another pharmaceutical company. Stocks in the pharmaceutical companies involved showed positive movement last week.